Who owns Madrigal Pharmaceuticals (MDGL)? Superinvestor holders

5 superinvestors of the 157 tracked here hold Madrigal Pharmaceuticals (MDGL) in their latest 13F filing, with $2.3B between them. John Paulson gives it the most weight: 27.9% of the reported portfolio. In their latest reported quarter, Brandon Haley opened a position; Julian and Felix Baker and Ken Griffin added; John Paulson reduced.

Ron Baron sold out of it in their latest quarter.

Hold it now
5
of 157 tracked
Combined value
$2.3B
Bought / sold
3 / 2
last quarter

Key facts

Superinvestors holding it
5 of 157
Biggest holder
Julian and Felix Baker, $1.2B
Largest weight
John Paulson, 27.9%of their portfolio
Combined value
$2.3B
Bought last quarter
3
Sold last quarter
2

From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.

Superinvestors holding MDGL, latest filings
#InvestorShare of their portfolioValueSharesLast quarterShares movedQuarter
1John PaulsonPaulson & Co.27.9%$719.5M1.34M▼ Reduced 3.8%−52.21KQ2 2026
2Julian and Felix BakerBaker Bros. Advisors5.77%$1.2B2.14M▲ Added 0.07%+1.5KQ2 2026
3Brandon HaleyHolocene Advisors0.19%$82.1M152.92KNew+152.92KQ2 2026
4Takis SparaggisAlkeon Capital Management0.17%$40.3M80KNo change0Q3 2026
5Ken GriffinCitadel Advisors0.16%$272.4M507.23K▲ Added 12%+53.37KQ2 2026

Sold out last quarter

Quarter by quarter

Superinvestor ownership of MDGL by quarter
QuarterFilings inHoldersCombined sharesCombined valueBoughtSold
Q3 202692180K$40.3M01
Q2 202615754.22M$2.3B32
Q1 202615764.3M$2.2B23
Q4 202515754.12M$2.4B12
Q3 202515754.2M$1.9B31
Q2 202515734.07M$1.2B12
Q1 202515644.47M$1.5B20
Q4 202415634.02M$1.2B00

A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.

Each holder's shares

Shares of MDGL held by each superinvestor, by quarter
InvestorQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Takis Sparaggis80K80K80K240K120K———
Julian and Felix Baker·2.14M2.14M2.14M2.14M1.98M1.97M1.97M
John Paulson·1.34M1.39M1.71M1.91M2.09M2.1M2.04M
Ken Griffin·507.23K453.84K—————
Brandon Haley·152.92K————390.55K—
Steve Cohen·—225.51K—————
Andrew Spokes——3.32K3.32K3.32K3.32K3.32K3.32K
Robert Pitts·——26.85K29.8K———

A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.

Questions and answers

Which superinvestors own MDGL?

In their latest 13F filings: John Paulson (27.9% of the portfolio, $719.5M), Julian and Felix Baker (5.77% of the portfolio, $1.2B), Brandon Haley (0.19% of the portfolio, $82.1M), Takis Sparaggis (0.17% of the portfolio, $40.3M), Ken Griffin (0.16% of the portfolio, $272.4M).

Who bought MDGL last quarter?

Julian and Felix Baker (added 0.1%), Brandon Haley (new position), Ken Griffin (added 12%). “Last quarter” is each investor's latest reported quarter.

Who sold MDGL last quarter?

Reduced: John Paulson (3.8% fewer shares). Sold out entirely: Ron Baron (was $2.4M).

How current is this?

It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.

Learn

Cite this page

Funkfolio, “Who owns Madrigal Pharmaceuticals (MDGL)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/MDGL/superinvestors

Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.

Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to MDGL by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.